Your Clinical Trial Supply Partner
Get Started
The acquisition combined capabilities for pharmaceutical and biotech clients in both clinical and commercial stages. Creapharm’s clinical packaging and distribution services, commercial packaging operations, and bioservices are now Creapharm, a Myonex company.
Clinical Trial Supply Management
Commercial Packaging
Biotherapies & ATMP Supply Chain Management
To simplify our services for our clients, the Creapharm brand will become Myonex in 2025. This transition will not impact your current services but will streamline your experience under the unified Myonex brand.
This rebranding does not mean any changes to the French services or facilities, and will not change anything in the daily business of our clients. We will continue to combine the local strengths and expertise of the US, UK, German and French teams to offer the best services for our clients.
Pharma and Biotechs Served
years in industry
patient-centric experts
global locations
depots globally
Myonex and Creapharm have worked together historically. The decision came from a desire from both companies to offer our clients better services while sharing vision and values.
The acquisition represents an important investment in Myonex and Creapharm’s growth to meet your growing clinical trial supply and project needs while maintaining the values that you know: speed, flexibility, quality and reducing costs. As a combined company, Myonex offers you expanded clinical trial packaging capabilities, commercial packaging and bioservices (storage of biological material – drugs (ATMPs), samples and raw materials – in -80°C or below -150°C, and adequate supply chain).
Read the press release here.
For Myonex’s clients we can offer you more flexibility for your EU clinical trials and additional capabilities:
For Creapharm’s clients we can offer you:
We can start working with you now to determine the best path forward for your project needs, giving you access to the full suite of services needed.
We do not anticipate any delays or problems for our projects. Our business is operating normally and will continue to work normally at any time, and we commit to all agreed services and deadlines. The combination will have no impact on our day-to-day business.
There is no impact on your current project. If there’s an added service you’d like to explore with this acquisition, we are happy to look at how to best offer it to you.
Your Project Manager or point of contact will remain the same – we’re just adding new services and expertise for you!
Absolutely. There are no changes or interruptions to our contracts, services, or commitments for supported trials.
Both Myonex and Creapharms have a strong, robust and compliant Quality System that will continue to operate in parallel.
Synergies to combine the best in class will be pursued through combined teams while ensuring that the client timelines and level of compliance are maintained.
While no immediate changes are needed to existing contracts, if (and only if) the client needs additional services from Creapharm or Myonex, there may be a need to update our contracts to include Myonex´s or Creapharm’s services and locations to the respective MSAs and QTAs, as applicable. In this case, we will work with you to enact any such changes.
Additionally, all payment and billing information will remain unchanged. We will notify you separately in the event any billing or payment information changes may be needed in the future.
We anticipate a significant number of client audit requests and will make every effort to accommodate as many audits as possible without disrupting current operations. Timing of audits/audit priority will be based on a number of factors, including but not limited to:
Please work with your main point of contact to request your audit.
